The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 12, 2015

Filed:

May. 22, 2009
Applicants:

Chikateru Nozaki, Kikuchi, JP;

Kazuyoshi Kaminaka, Kikuchi, JP;

Junichi Matsuda, Kikuchi, JP;

Takaaki Terahara, Tsukuba, JP;

Tetsuji Kuwahara, Tsukuba, JP;

Seiji Tokumoto, Tsukuba, JP;

Inventors:

Chikateru Nozaki, Kikuchi, JP;

Kazuyoshi Kaminaka, Kikuchi, JP;

Junichi Matsuda, Kikuchi, JP;

Takaaki Terahara, Tsukuba, JP;

Tetsuji Kuwahara, Tsukuba, JP;

Seiji Tokumoto, Tsukuba, JP;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61M 31/00 (2006.01); A61K 39/145 (2006.01); A61B 17/20 (2006.01); A61M 37/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/145 (2013.01); A61B 17/205 (2013.01); A61K 2039/541 (2013.01); A61K 2039/545 (2013.01); A61M 37/0015 (2013.01); A61M 2037/0046 (2013.01); A61M 2037/0061 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16234 (2013.01);
Abstract

The present invention provides a method for enhancing the immunogenicity using a microneedle device capable of enhancing the immunogenicity of an influenza vaccine. According to the method for enhancing the immunogenicity using the present microneedle device, a microneedle device having microneedles made of polylactic acid, coated with an influenza vaccine composed of an antigen having type A strain (H1N1), type A strain (H3N2), and type B strain as active ingredients is brought into direct contact with the skin so as to transcutaneously administer the aforementioned influenza vaccine. After the transcutaneous administration, lauryl alcohol is applied to the site of the skin where the microneedle device has been brought into direct contact.


Find Patent Forward Citations

Loading…